CMFRI to commercialise seaweed-based product 

A Memorandum of Understanding (MoU) has been signed between CMFRI and Kerala-based company Emineotech for the commercial production 

The ICAR-Central Marine Fisheries Research Institute (CMFRI) has announced that Cadalmin LivCure extract, a patent-protected nutraceutical product developed by the researchers at CMFRI from seaweeds, against non-alcoholic fatty liver disease, will hit the market soon.

A Memorandum of Understanding (MoU) has been signed between CMFRI and Kerala-based company Emineotech for the commercial production and marketing of the product.

A unique blend of 100 per cent natural bioactive ingredients extracted from select seaweeds, the product is made of an eco-friendly green technology to improve liver health, and is the ninth nutraceutical developed by the CMFRI.

According to Dr A Gopalakrishnan, CMFRI director, “Commercialisation of the product will be greatly beneficial to a large number of people suffering from non-alcoholic fatty liver disease as it helps improve liver health, reduce disposition of fatty substance and maintain other liver/lipid parameters within the clinically acceptable limits.” 

A Memorandum of Understanding (MoU) has been